WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
FDA Launches Website for Allegations Against Medical Device Manufacturers
Alerts
October 31, 2016

The U.S. Food and Drug Administration (FDA) recently launched a website1that will now make it easier to report allegations of medical device manufacturer misconduct to the agency.2Misconduct reports were historically submitted electronically (e.g., by email) or by letter. As many reporters wished to maintain anonymity, third parties (e.g., law firms) were often engaged to submit these reports. And once a third-party report was submitted, it was difficult to determine if the FDA commenced an investigation until an enforcement action was made public.

The FDA's new website and simplified reporting form are intended to lower barriers to reporting alleged medical device regulatory violations, to streamline the reporting process, and to provide an avenue to track resulting outcomes.3For example, a report may still be made anonymously4by filling out and submitting the FDA's Allegations of Regulatory Misconduct Form. Having a form that can be directly submitted to FDA via the web streamlines the reporting process. Also, as is currently the process, the reporter will receive a letter that acknowledges report submission and provides a tracking number. The tracking number can be used—in conjunction with Freedom of Information Act (FOIA) requests—to determine the outcome of the FDA's investigation resulting from the report. Again, whether the agency actually commences an investigation is not made public

The FDA requests reporters to submit sufficient information to allow the agency to make a detailed investigation of the allegation (including supporting documentation when necessary). Also, only medical device regulatory violation matters qualify for reporting through the FDA's new form. Reports associated with FDA-regulated drugs, biologics, dietary supplements, and cosmetics should be made to other departments of the FDA.5

For questions about reporting medical device regulatory violations, dealing with an FDA investigation following a reported violation, or any medical device regulatory matter, please contact David Hoffmeister or any member of the FDA regulatory practice at Wilson Sonsini.


1"Reporting Allegations of Regulatory Misconduct," FDA (2016); available at: http://www.fda.gov/MedicalDevices/Safety/ReportingAllegationsofRegulatoryMisconduct/default.htm?source=govdelivery&utm_medium=email&utm_ source=govdelivery.
2"Allocations of Regulatory Misconduct Form," FDA (2016); available at: http://www.fda.gov/MedicalDevices/Safety/ReportingAllegationsofRegulatoryMisconduct/ucm526129.htm.
3Reports can be submitted directly using the FDA's web-based form. Alternatively, reports can also be submitted by regular mail and email. In some instances, a report may use more than one submission method (e.g., the report can be made using the FDA’s web-based form, but supporting documents may be emailed).
4Anonymity is not absolute. The agency notes that: "The FDA will not share your identity or contact information with anyone outside the FDA unless required to do so by law, regulation, or court order." Also, given that some state actors are known to employ full-time, technically advanced hackers, there is always a de minims possibility that a hacking and subsequent disclosure may remove the vail of anonymity.
5Some of these reports may also be submitted online.

Contributors

  • David M. Hoffmeister
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.